投资个人养老金，既可以为自己的养老增添一份保障，还能享受个税递延的优惠。 ◆◆◆ 个人养老金账户如何开通？5大品种如何投资？ ▼点击阅读原 文，免费学习大额家庭资产配置课程 这里有一门限时免费的福利课程，介绍了个人养老金的投资方法。 文 | 银行螺丝钉 （转载请注明出处） 想要获取这个课程，可以添加下方「课程小助手」，回复「 养老金 」领取哦～ 更有课程笔记、思维导图，帮您快速搞懂课程脉络，学习更高效。 ...

Core Insights - The correlation between Bitcoin price fluctuations and Coinbase stock price movements highlights the interconnectedness of cryptocurrency and traditional financial markets [1][4] - Morgan Stanley predicts a significant influx of retail investment into the U.S. stock market, potentially leading to a 10% increase in stock prices [1][6] Group 1: Market Dynamics - Coinbase's stock price tends to experience significant volatility when Bitcoin's price fluctuates by over 10% within 24 hours, attracting attention from cryptocurrency investors towards U.S. trading platforms [1] - Major U.S. trading platforms like TD Ameritrade and E*TRADE offer regulatory compliance and transparency, contrasting with some cryptocurrency exchanges [3][11] - The U.S. stock market is expected to see a surge of $500 billion in retail investments, driven by individual investors, enhancing market activity [4][6] Group 2: Trading Strategies and Tools - U.S. trading platforms provide a variety of financial derivatives that cater to cryptocurrency users, including zero-commission trading and T+0 day trading features [4] - XBIT decentralized exchange offers advanced trading features, such as optimized order matching engines, enabling efficient trading even during peak times [4] - The use of risk hedging tools varies, with U.S. investors utilizing blockchain ETFs for downside protection, while cryptocurrency users employ multi-currency liquidity pools [4][11] Group 3: Investment Opportunities - The U.S. stock market hosts numerous high-quality blockchain companies, serving as a bridge between traditional finance and the crypto world [6] - XBIT's unique listing mechanism, which combines community voting and smart contract screening, enhances the innovation potential of its token offerings [6] - The average return for early participants in the 37 listed Web3 projects on XBIT is 3.2 times, with 8 of these projects expected to list on U.S. or Hong Kong stock exchanges [6][11] Group 4: Cross-Market Operations - The trading hours of the U.S. stock market complement the 24-hour trading of cryptocurrencies, allowing for arbitrage opportunities during market closures [7] - XBIT has developed tools to convert market indicators between U.S. stocks and cryptocurrencies, facilitating cross-market trading strategies [7] - The anticipated increase in market volatility, as predicted by Morgan Stanley, may further enhance the utility of these cross-market tools [7]

Meeting Overview - The 31st temporary meeting of the 8th Supervisory Board of Meinian Health Industry Holdings Co., Ltd. was held on July 11, 2025, via electronic means, with all three supervisors present [1][2]. Proposal for Asset Acquisition - The company plans to acquire equity stakes in 11 companies, including Hengyang Meinian Health Examination Center Co., Ltd., and minority stakes in 5 subsidiaries, including Zhengzhou Meijian Health Management Co., Ltd., through a share issuance [1][2][3]. Approval of Proposals - The Supervisory Board approved the proposal regarding the company's compliance with conditions for issuing shares to purchase assets, with a unanimous vote of 3 in favor [2][3]. - The proposal for the share issuance to purchase assets and related transactions was also approved, with a unanimous vote of 3 in favor [2][3]. Transaction Details - The transaction involves 37 counterparties, including individuals and companies, with specific equity stakes and transaction prices outlined for each [3][4]. - The transaction prices for key stakes include: - 84% of Hengyang Meinian for 33.6 million yuan - 81% of Ningde Meinian for 30.78 million yuan - 75% of Yantai Meinian for 35.8125 million yuan - 49% of Yantai Meinian Fudian for 12.25 million yuan - 90% of Feicheng Meinian for 22.5 million yuan [3][4]. Share Issuance Pricing - The share issuance price is set at 4.74 yuan per share, which is not less than 80% of the average trading price over the previous 120 trading days [5][6]. - The issuance price may be adjusted based on market conditions during the period from the pricing base date to the issuance date [6][7]. Lock-up Period and Profit Distribution - A lock-up period of 36 months is established for shares acquired by the counterparty, with conditions for extension based on stock performance [9][10]. - The profits generated during the transition period will belong to the company, while losses will be compensated by the counterparties based on their ownership percentages [10][11]. Compliance and Regulatory Approvals - The proposals will be submitted to the shareholders' meeting for approval, requiring a two-thirds majority of the voting rights present [2][11]. - The company has confirmed compliance with relevant laws and regulations regarding the asset acquisition and share issuance [12][13]. Future Shareholder Returns - The company has developed a three-year shareholder return plan for 2025-2027 to enhance shareholder value and ensure reasonable returns [26].

Meeting Announcement - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 28, 2025, at 14:50 in Shanghai [1][2] - The meeting will combine on-site voting and online voting, with online voting available from 9:15 to 15:00 on the same day [1][2] Voting Procedures - Shareholders can choose either on-site voting or online voting, and duplicate votes will be counted based on the first submission [2] - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [6][7] Agenda Items - The meeting will review several proposals, including the issuance of shares for asset acquisition and related transactions [4][12] - Proposals require a two-thirds majority of valid votes from attending shareholders, with related shareholders required to abstain from voting on certain items [6][12] Compliance and Reporting - The proposals have been approved by the company's board and supervisory committee, and details were published in various financial news outlets [5][12] - The company will ensure compliance with relevant regulations regarding asset restructuring and share issuance [5][13]

Core Viewpoint - The company plans to acquire significant stakes in multiple health management subsidiaries through a share issuance, which is expected to enhance its asset scale and profitability without diluting immediate returns per share [1][3]. Group 1: Transaction Details - The company intends to purchase 84% of Hengyang Meinian Health Checkup Center, 81% of Ningde Meinian Health Management, and several other stakes in various health management companies, totaling multiple acquisitions [1]. - The transaction is structured to ensure that the company's earnings per share (EPS) will not be diluted post-transaction, with projected increases in net profit attributable to the parent company [2][3]. Group 2: Measures to Mitigate Dilution Risks - The company plans to accelerate the integration of the acquired companies to enhance profitability and operational efficiency [3]. - A commitment to improve corporate governance and operational efficiency has been established, ensuring a robust management structure and clear responsibilities among various governance bodies [4]. - The company will refine its profit distribution policy to ensure fair returns to all shareholders while maintaining sustainable growth [6]. Group 3: Commitments from Stakeholders - The actual controller and senior management have issued commitments to uphold measures that protect immediate returns, ensuring no undue interference in company operations [6]. - Specific commitments include linking compensation plans to the execution of measures aimed at mitigating dilution of immediate returns [6].

Core Viewpoint - The company intends to acquire significant equity stakes in various health management and inspection centers through a share issuance, which complies with the relevant regulations of the Major Asset Restructuring Management Measures for Listed Companies [1][2][3] Group 1: Transaction Details - The company plans to purchase 84% of Hengyang Meinian Health Examination Center Co., Ltd., 81% of Ningde Meinian Health Management Co., Ltd., 75% of Yantai Meinian Health Management Co., Ltd., and several other stakes in various health management companies [1] - The transaction includes minority stakes in several subsidiaries, such as 47.37% in Zhengzhou Meijian Health Management Co., Ltd. and 49% in Guangzhou Huadu District Meinian Health Management Co., Ltd. [1] Group 2: Compliance with Regulations - The board has conducted a thorough analysis confirming that the transaction meets the conditions outlined in Article 11, Article 43, and Article 44 of the Major Asset Restructuring Management Measures [2] - The transaction does not involve any arrangements for phased issuance of shares for asset purchase, ensuring compliance with regulatory requirements [2][3] - The board believes that the transaction will not lead to significant adverse effects on competition or independence, and it can be completed within the agreed timeframe [2][3]

Core Points - The company intends to acquire significant equity stakes in multiple health management and inspection centers through a share issuance [1][2] - The board believes that the company does not fall under any prohibitive conditions outlined in the newly implemented "Regulations on the Registration Management of Securities Issuance by Listed Companies" [2] Group 1 - The company plans to purchase 84% of Hunan Meinian Health Examination Center, 81% of Ningde Meinian Health Management, 75% of Yantai Meinian Health Management, and several other stakes in various health management companies [1] - The board has conducted a thorough analysis and concluded that there are no disqualifying conditions for the share issuance, such as negative audit opinions or administrative penalties [2] - The board's assessment confirms compliance with the relevant regulations, ensuring the legitimacy of the upcoming transaction [2]

发行股份购买资产暨关联交易报告书（草案）与预案差异情况 对比说明 美年大健康产业控股股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日 披露了《美年大健康产业控股股份有限公司发行股份购买资产暨关联交易预案》 （以下简称"重组预案"）。 《关于 <美年大健康产业控股股份有限公司发行股份购买资产暨关联交易报告书> （草案）>及其摘要的议案》等相关议案，现就《美年大健康产业控股股份有限 公司发行股份购买资产暨关联交易报告书（草案）》（以下简称"重组报告书"） 与重组预案内容的主要差异情况说明如下： 重组报告书章节 与重组预案主要差异说明 声明 释义 为便于投资者阅读理解，增加及更新部分释义内容。 及《盈利预测补偿协议》，更新本次交易的具体方案； 美年大健康产业控股股份有限公司 重大事项提醒 产评估作价情况、交易支付方式等内容； 策和审批程序、本次交易对中小投资者权益保护的安排； 易作价尚未确定的风险"、"本次交易方案调整的风险"； 重大风险提示 "收购整合风险"、"本次交易可能摊薄即期回报的风险"。 署的交易协议等情况更新本次交易具体方案；新增本次交易 方案调整； 第一节 本次交易概况 补充本次交易 ...

Core Viewpoint - The company intends to acquire significant equity stakes in multiple health management and medical examination companies through a share issuance, with a focus on ensuring the independence and fairness of the asset evaluation process [1][2][3] Group 1: Transaction Overview - The company plans to purchase 84% of Hunan Meinian Health Examination Center, 81% of Ningde Meinian Health Management, 75% of Yantai Meinian Health Management, and several other stakes in various health management companies [1] - The total stakes being acquired include significant minority interests in several companies, indicating a broad expansion strategy in the health management sector [1] Group 2: Evaluation Process - The company has engaged Jinzheng (Shanghai) Asset Appraisal Co., Ltd. as the asset evaluation agency, which is compliant with the Securities Law and has the necessary qualifications and experience [2] - The evaluation is based on a reference date of March 31, 2025, and aims to assess the total equity value of the target companies [2] Group 3: Evaluation Independence and Assumptions - The evaluation agency is independent, with no existing relationships or conflicts of interest with the company or the transaction parties, ensuring an unbiased assessment [2] - The assumptions set by the evaluation agency are reasonable and comply with national laws and market practices, reflecting the actual conditions of the assets [2] Group 4: Evaluation Methods and Fairness - The evaluation utilized both the income approach and asset-based approach, ultimately relying on the income approach for the final valuation of the equity [3] - The evaluation process adhered to principles of independence, objectivity, and fairness, resulting in a valuation that accurately reflects the market value of the assets as of the evaluation date [3] - The transaction pricing is based on the evaluation results, ensuring fairness and reasonableness, protecting the interests of the company and its minority shareholders [3]

Core Viewpoint - The independent directors of Meinian Onehealth Healthcare Holdings Co., Ltd. have approved a series of proposals regarding the acquisition of equity stakes in multiple companies through a share issuance, which is expected to enhance the company's business structure and profitability [1][2][3]. Group 1: Approval of Proposals - The independent directors have reviewed and approved the proposal for the company to issue shares for asset acquisition, confirming compliance with relevant laws and regulations [1]. - The transaction plan for issuing shares to purchase assets and related party transactions has been deemed reasonable and operable, benefiting the company's business structure and shareholder interests [2]. - The independent directors have also approved the draft report related to the share issuance for asset acquisition, affirming its compliance with legal requirements [2]. Group 2: Transaction Characteristics - The transaction involves acquiring stakes in 11 companies, including Hengyang Meinian Health Checkup Center Co., Ltd., and minority stakes in 5 subsidiaries, including Zhengzhou Meijian Health Management Co., Ltd. [1]. - The transaction is classified as a related party transaction due to the involvement of a company controlled by the actual controller of Meinian [3]. - It has been confirmed that the transaction does not constitute a major asset restructuring as the assets involved do not exceed 50% of the company's relevant financial metrics [4]. Group 3: Compliance and Procedures - The independent directors have confirmed that the transaction adheres to the regulatory requirements for major asset restructuring and does not involve any recent changes in control [4][5]. - The company has fulfilled all necessary legal procedures and submitted valid legal documents for the transaction [7]. - The evaluation agency selected for the transaction has been deemed independent, and the valuation methods used are considered reasonable and fair [7][9]. Group 4: Financial Aspects - The total transaction price for the equity stakes is approximately 427.78 million yuan [9]. - The company has conducted an analysis of the impact of the transaction on immediate returns and has proposed measures to mitigate any potential dilution of returns [8]. Group 5: Authorization and Future Steps - The board of directors has requested authorization from the shareholders' meeting to handle all matters related to the transaction, including adjustments to the transaction plan and execution of necessary agreements [10].